Kent Imaging and SerenaGroup® Research Foundation awarded prestigious AICE grant

September 22, 2020. Kent Imaging and SerenaGroup® Research Foundation, have received the prestigious Accelerating Innovations into Care (AICE)Market Access grant from Alberta Innovates, a research and innovation agency sponsored by the province of Alberta, Canada. AICE supports companies in commercializing innovative digital health technologies. The award will fund clinical trials investigating the novel diagnostic technology developed by Kent Imaging utilizing near infrared spectroscopy (SnapshotNIR). Kent has partnered with SerenaGroup® Research Foundation to conduct this pivotal research.

Near infrared spectroscopy measures oxygen levels in tissue in real time without the need for injected dyes or invasive probes.  SnapshotNIR captures the image without patient contact. The colors displayed on the screen correspond to the degree of tissue oxygenation:  blue represents low oxygen levels and red represents high.  At present, advanced wound and hyperbaric centers use transcutaneous oxygen (TCOM) to measure oxygenation; however, TCOM has numerous drawbacks: the results are operator dependent, it requires heated leads that are attached to the skin and the procedure takes an hour to complete.

The AICE grant will fund a multicenter head-to-head clinical trial comparing SnapshotNIR to TCOM. In addition, correlation between the SnapshotNIR readings and healing outcomes will allow the investigators to predict the best interventions for patients with diminished oxygenation. “Health innovators often face headwinds in generating the evidence necessary for implementing new solutions. The data generated in this trial will accelerate the path to impact for SnapshotNIR, and is fully aligned with our digital health strategy,” shared Tim Murphy, VP Health at Alberta Innovates.

“This new technology from Kent Imaging will allow clinicians to rapidly assess tissue oxygenation in patients with chronic wounds, which will avoid delays in diagnosis and treatment,” said Dr. Tomas Serena, Director of the SerenaGroup® Research Foundation. “I believe that SnapshotNIR will play a key role in limb preservation in our diabetic patients, allowing woundologists to identify the patients who will benefit from advanced modalities such as for hyperbaric oxygen therapy.”

“We are very excited to be working with Dr. Tomas Serena and the SerenaGroup® Research Foundation to establish definitively the value of SnapshotNIR in the prediction of wound healing. Kent Imaging’s goal is to provide innovative technology that helps physicians to heal wounds, improve outcomes and significantly reduce amputations. This study will take us a long way towards meeting this goal,” said Pierre Lemire, CEO at Kent Imaging. “We also want to acknowledge the ongoing support of the Alberta Government in bringing this paradigm changing technology to market.”

About Kent Imaging

Kent Imaging Inc., a Canadian company located in Calgary, Alberta, and leading innovator in oxygenation imaging, designs and manufactures imaging technology that employs near infrared spectroscopy to measure tissue oxygen saturation. The oxygenation information provides immediate insight into tissue viability supporting real-time decision making in wound care, vascular and surgical specialties to aid in the delivery of positive patient outcomes throughout the care continuum.  For more information about Kent Imaging, visit www.kentimaging.com.

About SerenaGroup® Research Foundation

The SerenaGroup® Research Foundation, a leader in wound healing research, conducts eight to nine clinical trials each year and publishes a dozen manuscripts annually. Dr. Serena has been the lead or Principal Investigator in over 100 clinical trials, including gene therapy, dressings, growth factors, topical and parenteral antibiotics, and CTP therapy.  His team has led the development of diagnostic imaging and biomarkers in the field of wound healing.  

About Alberta Innovates

Alberta Innovates invests in research, innovation and entrepreneurship to drive provincial economic growth and diversity. We ignite the power of innovation through our work with researchers, industry and entrepreneurs to move Alberta to a lower-carbon future, enhance the responsible use of land and water, and contribute to the improved health and well-being of Albertans.

Will Siewert Appointed Kent Imaging’s Vice President, Sales for the US Market

September 8, 2020. Kent Imaging announced today the appointment of Will Siewert as Vice President of Sales, USA.

Will Siewert is a multi-award winning strategic sales executive with nearly two decades of medical device experience, including commercial launches for perfusion assessment technologies of Spy, Luna, and Pinpoint. Prior to joining Kent Imaging in 2017 as the Sales Director, Mr. Siewert had roles as trainer and sales leader within multiple organizations including Lifecell, Karl Storz and Covidien. At Kent, Mr. Siewert is responsible for sales of the Snapshot product line, primarily in the reconstructive surgical and limb salvage markets, in the USA.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

New and novel methods of non-invasive vascular assessment: enhancing triage protocols in wound healing and limb salvage

This CE/CME/CECH webinar presented by Dr. Richard Neville, MD (Director, Inova Vascular) and moderated by Dr. Lee Rogers, DPM (Chief Medical Officer at Amputation Prevention Experts (APEx) Health Network), is supported through an unrestricted educational grant from Kent Imaging. A recording of the webinar will reside on the podiatry.com website for 12 months following the live event. Register now for what is sure to be an intriguing topic in the management of critical limb ischemia.

SnapshotNIR Shown to Correlate to TCOM in Recent Publication

Check out a new study measuring tissue oxygenation in hard-to-heal wounds published in the Journal of Wound Care , comparing the use of TCOM to NIRS imaging with SnapshotNIR. The lead author, Dr. Tom Serena, concluded that both forms of measurement were well correlated but that SnapshotNIR  provided a number of significant advantages: immediate point-of-care visualization of tissue oxygenation using a handheld device, the entire imaging procedure takes only a few minutes to perform and removes operator dependence, and with no patient contact, allows for measurements directly in the wound bed.  

SnapshotNIR Aids in Effective Clinical Decisions by Advancing Tissue Assessment

SnapshotNIR is the feature of an article titled “Assessing DFU Perfusion: Comparing the Tried & True to the Novel & New” published in the May 2020 issue of Today’s Wound Clinic. The authors, Windy Cole, DPM, and Stacey Coe, note the challenges and inaccuracy with standard non-invasive vascular assessment methods, such as TCOM, and seek to determine if near-infrared spectroscopy (NIRS) imaging can provide a more accurate picture of wound healing. Using a challenging diabetic foot ulcer case study, the authors conclude that SnapshotNIR is the future of managing wound care treatments for improved and timely healing. SnapshotNIR was able to track hemodynamic changes in wound tissues after revascularization, and that the changes noted in wound tissue oxygenation correlated to the clinical appearance of the wound. The imaging information captured added aided clinicians in determining appropriate and effective treatment choices for patients’ recovery. SnapshotNIR’s ability to produce instant and reproducible images, along with its portability makes it an excellent choice for clinicians and the healing of their patients’ wounds. 

Supporting Wound Care Services through Remote Diagnostic Imaging

I hope that you continue to stay safe in this challenging environment, while you strive to provide on-going care for your wound patients.  We appreciate that these are unprecedented times, and Kent Imaging is focused on supporting you and your patients through the “new normal” which is anything but.

We understand that proper wound care is essential to preserving tissue and limbs and that “time is tissue.” We’re seeing proactive clinics adopting telehealth and remote diagnostic technologies to assist with wound triage to ensure patients are effectively prioritized for inpatient care.

In order to assist with this transition, Kent Imaging has refocused its resources to meet the demand from existing SnapshotNIR customers to release an update that remotely provides an informative assessment of the wound and vascular status.  Our partners have been instrumental in the development of this solution and continue to determine the best way SnapshotNIR can help them keep their patients out of the hospitals.

By embracing new methods of care including remote diagnostics to support triage decisions, providers can better understand wound progression remotely, providing appropriate referrals to those who need them, and protecting the health of patients who are unable to come to the hospital or are at high risk for COVID-19.

Please don’t hesitate to contact Kent Imaging to learn more. We have set-up a support center to provide online access to technical and clinical expertise to assist your staff with remote deployment and image assessment.

Your sincerely,

This image has an empty alt attribute; its file name is Pierre-Lemire-Signature1945.png

Pierre Lemire

CEO, Kent Imaging

pierre@kentimaging.com

Dr. John Harper, Senior Medical Scientist at 3M Healthcare, joins Board at Kent Imaging

January 27, 2020. Kent Imaging announced today the addition of Dr. John Harper, Ph.D. to its Board of Directors and welcomes him as an investor in the organization. His addition to the board complements and strengthens its existing directors’ expertise in business, medicine and marketing by adding advanced product strategies and strong industry connections. 

“We are extraordinarily pleased with the addition of Dr. Harper to the Board of Directors and are honored to have him on the team” comments Don Chapman, Founder and Chairman of the Board at Kent Imaging. “He will contribute a wealth of knowledge, strategic insight, medical product development and commercialization experience to the Board.”

Dr. Harper brings over 35 years of research and healthcare industry experience to the table.  During his tenure at LifeCell, Dr. Harper oversaw the development of pivotal scientific and clinical data proving the utility of its regenerative products AlloDerm, Strattice, and GraftJacket.  He also led the introduction of Novadaq and SPY Elite technology to LifeCell for launching into the plastic surgery space. Currently, Dr. Harper is a Senior Medical Scientist at 3M – Medical Solutions Division, providing leadership over the company’s global technology and innovation outreach, as well as product portfolio strategy and execution. Prior to 3M’s recent acquisition of KCI, Dr. Harper led KCI’s Center for Advanced Research and Technology, as well served as Senior Vice President for Global Clinical and Regulatory Affairs.  Most recently as Chief Technology Officer at KCI, Dr. Harper was responsible for early stage innovation and technology development.  Dr. Harper received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, CA and the National Cancer Institute in Bethesda, MD. 

“I am joining Kent’s Board at a time when the need for advancing new technologies in all aspects of surgery and wound care at a cost-effective price point is critical. A number of years back, I took an interest in the imaging technology developed by the company, and am impressed by the progress to date and the direction Kent is taking. I am excited and honored to join the Board and this will provide me with the opportunity to lend my experience and expertise to further enhance growth of the organization” states Dr. Harper.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets near infrared imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

Advancing Tissue Assessment: SnapshotNIR imaging similar to ICG fluorescence angiography

A new study published by Jones, G. et al. in Plastic and Reconstructive Surgery (PRS) January 2020 highlights the comparable accuracy between SnapshotNIR and ICG fluorescence angiography in assessing flap outcome in the immediate post-operative period. The article “Snapshot Multispectral Imaging Is Not Inferior to SPY Laser Fluorescence Imaging When Predicting Murine Flap Necrosis” shares results that are extremely encouraging for the use of SnapshotNIR intraoperatively in flaps in a timely and non-invasive manner. https://journals.lww.com/plasreconsurg/Abstract/2020/01000/Snapshot_Multispectral_Imaging_Is_Not_Inferior_to.29.aspx

Easy-to-operate SnapshotNIR valuable in tracking wound healing progress with PACE therapy.

Dr. Windy Cole DPM, Kent State University, uses SnapshotNIR to assess chronic wound healing in a pulsed acoustic cellular expression (PACE) therapy case study. SnapshotNIR was shown to be “a very user friendly point-of-care imaging device to track weekly wound progress. It provided an objective means of evaluating wound response to PACE therapy.” Published in Today’s Wound Clinic® October 2019.

TWC1019_Cole

SnapshotNIR demonstrated to be clinically valuable in the management of CLI.

Continuous monitoring of the hemodynamic characteristics (perfusion of oxygenated blood) after revascularization is clinically relevant in monitoring and managing patients with critical limb ischemia (CLI). Handheld SnapshotNIR was used for longitudinal monitoring of tissue oxygenation to predict healing outcomes in patients with CLI at the AZH Wound and Vascular Center, Milwaukee, WI. “The hemodynamic changes measured using SnapshotNIR after endovascular revascularization and HBOT allow clinicians to use this technology to determine treatment protocols and understand healing characteristics in CLI.” Many additional benefits of this imaging technology were noted, including cost effectiveness, time efficiency and ability to integrate with existing EMR. Today’s Wound Clinic® September 2019.

https://www.todayswoundclinic.com/articles/using-near-infrared-spectroscopy-imaging-manage-critical-limb-ischemia